

CIPROFLOXACIN

an ingredient in the MPOX vaccine.

By Craig Paardekooper

Ciprofloxacin is an ingredient in the MPOX vaccine, Jynneos. As previously mentioned here, Jynneos is a repurposed Smallpox vaccine that has a serious side effect of inducing cardiac damage in more than 10% of recipients – see [here](#)

In this doc, we look at another ingredient in the MPOX vaccine called Ciprofloxacin.

Cipro, Levaquin and Avelox lawsuits **claimed patients suffered tendon rupture, neuropathy, and aortic aneurysms and dissections after taking the drugs**. Most of these cases have been resolved with confidential settlements. (settled out of court) . [See here](#)

I used the Eudra-vigilance dataset, download [here](#), to look at the frequency of every symptom associated with Ciprofloxacin. Here are the results. A downloadable spreadsheet of the results is also available here.

| SYMPTOM | FREQ | TOTAL | % |
|-------------------------|------|-------|------|
| neuropathy peripheral | 603 | 14233 | 4.24 |
| drug interaction | 320 | 14233 | 2.25 |
| pain | 258 | 14233 | 1.81 |
| acute kidney injury | 210 | 14233 | 1.48 |
| rash | 199 | 14233 | 1.4 |
| tendon rupture | 189 | 14233 | 1.33 |
| arthralgia | 157 | 14233 | 1.1 |
| nausea | 137 | 14233 | 0.96 |
| anxiety | 137 | 14233 | 0.96 |
| diarrhoea | 135 | 14233 | 0.95 |
| pain in extremity | 129 | 14233 | 0.91 |
| pruritus | 124 | 14233 | 0.87 |
| hypoesthesia | 122 | 14233 | 0.86 |
| tendonitis | 122 | 14233 | 0.86 |
| fatigue | 121 | 14233 | 0.85 |
| dyspnoea | 116 | 14233 | 0.82 |
| dizziness | 106 | 14233 | 0.74 |
| vomiting | 106 | 14233 | 0.74 |
| pyrexia | 104 | 14233 | 0.73 |
| myalgia | 100 | 14233 | 0.7 |
| nervous system disorder | 95 | 14233 | 0.67 |
| asthenia | 94 | 14233 | 0.66 |
| paraesthesia | 90 | 14233 | 0.63 |

| | | | |
|---|----|-------|------|
| depression | 89 | 14233 | 0.63 |
| drug ineffective | 88 | 14233 | 0.62 |
| injury | 86 | 14233 | 0.6 |
| mental disorder | 85 | 14233 | 0.6 |
| hypotension | 85 | 14233 | 0.6 |
| rash maculo-papular | 85 | 14233 | 0.6 |
| erythema | 82 | 14233 | 0.58 |
| international normalised ratio increased | 81 | 14233 | 0.57 |
| cardiovascular disorder | 79 | 14233 | 0.56 |
| emotional distress | 78 | 14233 | 0.55 |
| rotator cuff syndrome | 74 | 14233 | 0.52 |
| toxicity to various agents | 71 | 14233 | 0.5 |
| abdominal pain | 70 | 14233 | 0.49 |
| insomnia | 70 | 14233 | 0.49 |
| headache | 68 | 14233 | 0.48 |
| physical disability | 68 | 14233 | 0.48 |
| thrombocytopenia | 69 | 14233 | 0.48 |
| seizure | 69 | 14233 | 0.48 |
| tendon pain | 69 | 14233 | 0.48 |
| confusional state | 67 | 14233 | 0.47 |
| skin injury | 64 | 14233 | 0.45 |
| urticaria | 62 | 14233 | 0.44 |
| muscular weakness | 61 | 14233 | 0.43 |
| hypoglycaemia | 60 | 14233 | 0.42 |
| musculoskeletal injury | 59 | 14233 | 0.41 |
| gait disturbance | 58 | 14233 | 0.41 |
| drug hypersensitivity | 57 | 14233 | 0.4 |
| malaise | 56 | 14233 | 0.39 |
| back pain | 56 | 14233 | 0.39 |
| burning sensation | 55 | 14233 | 0.39 |
| stevens-johnson syndrome | 53 | 14233 | 0.37 |
| tendon disorder | 52 | 14233 | 0.37 |
| toxic epidermal necrolysis | 49 | 14233 | 0.34 |
| agranulocytosis | 48 | 14233 | 0.34 |
| renal failure | 45 | 14233 | 0.32 |
| weight decreased | 45 | 14233 | 0.32 |
| tremor | 46 | 14233 | 0.32 |
| muscle spasms | 45 | 14233 | 0.32 |
| neutropenia | 45 | 14233 | 0.32 |
| drug reaction with eosinophilia and systemic symptoms | 44 | 14233 | 0.31 |
| tubulointerstitial nephritis | 43 | 14233 | 0.3 |
| visual impairment | 43 | 14233 | 0.3 |
| urinary tract infection | 42 | 14233 | 0.3 |
| somnolence | 41 | 14233 | 0.29 |
| decreased appetite | 40 | 14233 | 0.28 |
| condition aggravated | 40 | 14233 | 0.28 |

| | | | |
|----------------------------|----|-------|------|
| cough | 39 | 14233 | 0.27 |
| hypersensitivity | 39 | 14233 | 0.27 |
| tinnitus | 39 | 14233 | 0.27 |
| palpitations | 39 | 14233 | 0.27 |
| blood creatinine increased | 35 | 14233 | 0.25 |

As you can see, neuropathy and tendon rupture have prominent ranks, occurring in 4.24% and 1.33% of all reported cases in Eudra-vigilance.

| SYMPTOM | FREQ | TOTAL | % |
|------------------------------------|------|-------|------|
| neuropathy peripheral | 603 | 14233 | 4.24 |
| polyneuropathy | 14 | 14233 | 0.1 |
| peripheral sensory neuropathy | 6 | 14233 | 0.04 |
| peripheral sensorimotor neuropathy | 3 | 14233 | 0.02 |
| autonomic neuropathy | 1 | 14233 | 0.01 |
| demyelinating polyneuropathy | 1 | 14233 | 0.01 |
| small fibre neuropathy | 2 | 14233 | 0.01 |
| peripheral motor neuropathy | 2 | 14233 | 0.01 |
| axonal neuropathy | 2 | 14233 | 0.01 |
| mononeuropathy multiplex | 1 | 14233 | 0.01 |
| diabetic neuropathy | 1 | 14233 | 0.01 |
| mononeuropathy | 1 | 14233 | 0.01 |

However, with neuropathy we should include both “nervous system disorder” and “mental disorder”, “neuralgia”, and “nerve pain”.

| SYMPTOM | FREQ | TOTAL | % |
|--------------------------------|------|-------|------|
| mental disorder | 85 | 14233 | 0.6 |
| mental status changes | 8 | 14233 | 0.06 |
| mental impairment | 7 | 14233 | 0.05 |
| mental disability | 1 | 14233 | 0.01 |
| segmental diverticular colitis | 1 | 14233 | 0.01 |

| SYMPTOM | FREQ | TOTAL | % |
|---------------------------------------|------|-------|------|
| nervous system disorder | 95 | 14233 | 0.67 |
| nervousness | 8 | 14233 | 0.06 |
| autonomic nervous system imbalance | 3 | 14233 | 0.02 |
| tuberculoma of central nervous system | 2 | 14233 | 0.01 |

| SYMPTOM | FREQ | TOTAL | % |
|-------------------------|------|-------|------|
| neuralgia | 17 | 14233 | 0.12 |
| occipital neuralgia | 1 | 14233 | 0.01 |
| post herpetic neuralgia | 1 | 14233 | 0.01 |

| SYMPTOM | FREQ | TOTAL | % |
|--------------------------------|------|-------|------|
| peripheral nerve injury | 23 | 14233 | 0.16 |
| nerve injury | 8 | 14233 | 0.06 |
| hypoglossal nerve paresis | 1 | 14233 | 0.01 |
| nerve degeneration | 1 | 14233 | 0.01 |
| peripheral nerve destruction | 1 | 14233 | 0.01 |
| peripheral nerve lesion | 1 | 14233 | 0.01 |
| cranial nerve disorder | 1 | 14233 | 0.01 |
| facial nerve disorder | 2 | 14233 | 0.01 |
| olfactory nerve disorder | 1 | 14233 | 0.01 |
| peroneal nerve palsy | 1 | 14233 | 0.01 |
| cranial nerve palsies multiple | 1 | 14233 | 0.01 |

This raises the % of reports with neuropathy to 6.42% or 1 in 15 reports.

For the symptoms in the lawsuits, you can see that the symptoms with highest incidence are neuropathy and tendon disorders. If we include tendonitis, tendon pain and tendon disorder, then we have a total of 3.23%, which is similar to the incidence of neuropathy. So tendon disorder occurs for 1 in 30 reports.

| SYMPTOM | FREQ | TOTAL | % |
|------------------------|------|-------|------|
| tendon rupture | 189 | 14233 | 1.33 |
| tendonitis | 122 | 14233 | 0.86 |
| tendon pain | 69 | 14233 | 0.48 |
| tendon disorder | 52 | 14233 | 0.37 |
| tendon injury | 16 | 14233 | 0.11 |
| tendon discomfort | 9 | 14233 | 0.06 |
| tendon sheath disorder | 1 | 14233 | 0.01 |
| tendon calcification | 1 | 14233 | 0.01 |

| SYMPTOM | FREQ | TOTAL | % |
|-------------------------|------|-------|------|
| aortic aneurysm | 14 | 14233 | 0.1 |
| aneurysm ruptured | 1 | 14233 | 0.01 |
| vascular pseudoaneurysm | 1 | 14233 | 0.01 |

| SYMPTOM | FREQ | TOTAL | % |
|---------------------------|------|-------|------|
| aortic dissection | 7 | 14233 | 0.05 |
| artery dissection | 2 | 14233 | 0.01 |
| aortic dissection rupture | 1 | 14233 | 0.01 |

So, the Eudra data gives us an overview of which symptoms are most likely, and helps us rank those symptoms in order of priority for further investigation.

We can see that peripheral neuropathy and tendon injury are the two key pathologies associated with this drug. Even though the lawsuits did not pick up on this, acute kidney injury also appears to be a significant pathology here.

The allegations of the prosecutors seem confirmed by the high incidences of neuropathy and tendon injury.

Levofloxacin

Levofloxacin belongs to the same family of drugs as Ciprofloxacin. The Eudra data contains 33985 symptom instances associated with this drug. From this we can determine a symptom profile.

You can see that tendonitis and tendon rupture are still an issue with Levofloxacin, but occur with a higher incidence compared to Ciprofloxacin.

| SYMPTOM | FREQ | TOTAL | % |
|--------------------------------|------|-------|------|
| rash | 908 | 33985 | 2.67 |
| pruritus | 836 | 33985 | 2.46 |
| tendonitis | 723 | 33985 | 2.13 |
| off label use | 556 | 33985 | 1.64 |
| tendon rupture | 535 | 33985 | 1.57 |
| dyspnoea | 468 | 33985 | 1.38 |
| erythema | 421 | 33985 | 1.24 |
| urticaria | 418 | 33985 | 1.23 |
| arthralgia | 411 | 33985 | 1.21 |
| nausea | 404 | 33985 | 1.19 |
| pyrexia | 387 | 33985 | 1.14 |
| tendon pain | 355 | 33985 | 1.04 |
| vomiting | 324 | 33985 | 0.95 |
| pain in extremity | 307 | 33985 | 0.9 |
| myalgia | 300 | 33985 | 0.88 |
| drug ineffective | 296 | 33985 | 0.87 |
| pain | 289 | 33985 | 0.85 |
| dizziness | 281 | 33985 | 0.83 |
| hypersensitivity | 277 | 33985 | 0.82 |
| drug interaction | 277 | 33985 | 0.82 |
| diarrhoea | 278 | 33985 | 0.82 |
| hepatic function abnormal | 255 | 33985 | 0.75 |
| seizure | 248 | 33985 | 0.73 |
| electrocardiogram qt prolonged | 215 | 33985 | 0.63 |
| asthenia | 208 | 33985 | 0.61 |
| anaphylactic reaction | 208 | 33985 | 0.61 |

Lawsuits

The three central injuries in fluoroquinolone lawsuits were peripheral neuropathy, aortic aneurysm and tendon rupture. The main allegation in these litigations is that manufacturers failed to warn of side effects.

Peripheral Neuropathy Lawsuits

According to the original transfer order for peripheral neuropathy lawsuits, plaintiffs in this litigation claimed manufacturers failed to warn of the risk of peripheral neuropathy and manufactured a dangerous product. After bellwether trials were selected in 2017, they never proceeded to trial and were resolved confidentially.

A cancer survivor, Ann Winslow, told Drugwatch the story of how she suffered from neuropathy and chronic nerve pain after taking Cipro and Levaquin. She has since passed away.

[Ann Winslow, fluoroquinolone patient](#)

“I couldn’t get to the bathroom on my own. I couldn’t even make a cup of coffee. I had to wear gloves because God forbid I touch something. The pain in my hands was so bad,” Winslow said. “You sit on the couch with your arms around your knees, you don’t want your feet to touch anything.”

In August 2015, the U.S. Judicial Panel on [Multidistrict Litigation](#) ordered all federal neuropathy cases to be transferred to the District of Minnesota for consolidated pretrial proceedings. The panel assigned the cases to U.S. District Judge John R. Tunheim.

At the time, about 80 actions were pending in nearly 40 federal districts. Additional cases (some of which were transferred to the MDL) were also pending in state court in California, Pennsylvania, New Jersey and Oklahoma.

The remaining lawsuits in the MDL have been slowly resolved with confidential settlements, though [the MDL remained open in July 2024](#).

Cipro, Levaquin & Avelox Tendon Rupture Lawsuits

People who filed Cipro, Levaquin and Avelox tendon rupture lawsuits claim the first warnings came after the FDA added a black box warning in 2008, but defendants knew as early as 2003 and didn’t warn sooner. These were some of the earliest fluoroquinolone antibiotic lawsuits.

Rachel Brummert told Drugwatch she has suffered 24 tendon ruptures after taking Levaquin. The first happened only a month after she took the drug.

“My Achilles tendon spontaneously ruptured in my right ankle and balled up in my calf. At age 36, that was the first of dozens of tendon ruptures,” Brummert said.



“My Achilles tendon spontaneously ruptured in my right ankle and balled up in my calf. At age 36, that was the first of dozens of tendon ruptures.”

Rachel Brummert, Levaquin user

Judge Tunheim also oversaw pretrial proceedings for a separate MDL involving Levaquin. Plaintiffs in that MDL were prescribed Levaquin and allege that it causes tendon rupture.

Plaintiffs in the tendon rupture MDL claim the defendants, [Johnson & Johnson](#) and Ortho-McNeil Pharmaceutical Inc., failed to adequately warn of the side effect.

The plaintiffs began filing lawsuits in late 2006, and the MDL was created in 2008. Around the same time, the FDA added a black box warning to fluoroquinolones for the increased risk of tendinitis and tendon rupture.

Levaquin Tendon Rupture Jury Verdict

John Schedin’s case was the first to go to trial out of about 2,600 tendon rupture claims across the country. In December 2010, a jury awarded Schedin \$700,000, finding that Johnson & Johnson failed to warn about the risk of tendon rupture with Levaquin.

Disabling, Potentially Irreversible Serious Reactions

fluoroquinolones assoc. with tendinitis/tendon rupture, peripheral neuropathy, and CNS effects that may occur together; tendinitis/tendon rupture may occur during tx or months after tx D/C; incr. tendinitis/tendon rupture risk in all ages; risk further incr. in older pts >60 yo, pts taking corticosteroids, and pts w/ kidney, heart, or lung transplant

Avoid in Myasthenia Gravis

fluoroquinolones may exacerbate muscle weakness in pts w/ myasthenia gravis

Reserve Fluoroquinolone Use

for pts w/ no alternative tx options for acute bacterial sinusitis, acute bacterial exacerbation of chronic bronchitis, or uncomplicated UTI

Levaquin Black Box Warning. The FDA added a warning for the increased risk of tendinitis and tendon rupture

The jury also awarded \$1,115,000 in punitive damages, but it was later reversed. The second and third bellwether trials were tried in June 2011 and January 2012, respectively. Both resulted in jury verdicts in favor of Johnson & Johnson and Ortho-McNeil Pharmaceutical Inc.

About 2,049 total actions were filed under the MDL. Records show hundreds of cases ended in settlements. Others were transferred or remanded and subsequently dismissed. The U.S. Judicial Panel on Multidistrict Litigation officially closed the MDL in July 2017.

NHS

[Ref](#)

“These serious side effects can happen in less than 1 in 100 people. Stop taking ciprofloxacin and call your doctor or call 111 now if:

- *you, or your friends or family, notice changes in your mood or behaviour*
- *you have severe tiredness, feel anxious, low in mood or depressed, or have panic attacks*
- *you have **confusion**, or have difficulty sleeping **or remembering things***
- *you have **confusion**, anxiety or depression*
- *you have muscle weakness, pain or **swelling in your joints or tendons**. **This often begins in the ankle or calf, but could also be in your shoulder, arms or legs. It can happen in the first 2 days of taking ciprofloxacin or even several months after stopping**. It is more common in children*
- *you have pain or abnormal sensations (such as pins and needles that do not go away, tingling, tickling, numbness or burning) or weakness in your body, especially in your legs or arms”*

Clinical Literature

<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2921747/>

“The Dosage Makes the Poison”

a) Treatment of infections with ciprofloxacin tablets:

We see typical doses in adults of 1000 mg up to even 1500 mg a day.

<https://www.mayoclinic.org/drugs-supplements/ciprofloxacin-oral-route/proper-use/drg-20072288>

(b) Jynneos Vaccine:

ciprofloxacin \leq 0.005 micrograms – which is 200,000,000 times less than the 1000 mg daily of a treatment with pills. It is a minimum amount to ensure that the vaccine does not have bacterial contamination.

The vaccine consists of two 0.5 mL doses a few weeks apart. They add up to 1 mL, about 1 gram of liquid. Even if the amount of ciprofloxacin were much higher than stated, it could not exceed 1 gram (1000 mg), the typical single-day dose for treating an infection with pills. It seems unlikely that the issue with the MPOX vaccine will be Ciprofloxacin, though we should be wary that the actual dose may vary considerably from the stated dose.

When thawed, JYNNEOS (Smallpox and Monkeypox Vaccine, Live, Non-replicating) is a milky, light yellow to pale white colored suspension for subcutaneous injection.

JYNNEOS is a live vaccine produced from the strain Modified Vaccinia Ankara-Bavarian Nordic (MVA-BN), an attenuated, non-replicating orthopoxvirus. MVA-BN is grown in primary Chicken Embryo Fibroblast (CEF) cells suspended in a serum-free medium containing no material of direct animal origin, harvested from the CEF cells, purified and concentrated by several Tangential Flow Filtration (TFF) steps including benzonase digestion. Each 0.5 mL dose is formulated to contain 0.5×10^8 to 3.95×10^8 infectious units of MVA-BN live virus in 10 mM Tris (tromethamine), 140 mM sodium chloride at pH 7.7. Each 0.5 mL dose may contain residual amounts of host-cell DNA (\leq 20 mcg), protein (\leq 500 mcg), benzonase (\leq 0.0025 mcg), gentamicin (\leq 0.400 mcg) and ciprofloxacin (\leq 0.005 mcg).

JYNNEOS is a sterile vaccine formulated without preservatives. The vial stoppers are not made with natural rubber latex.

<https://www.mayoclinic.org/drugs-supplements/ciprofloxacin-oral-route/proper-use/drg-20072288>

Offsetting Some of the Effects of Ciprofloxacin ?

Here is an anecdotal report. I am including it because it suggests a possible way of lessening the probability of tendon injury.

“A really key message to get out here is that I had a really bad abscess infection once and that nothing was stopping it.. Ciprofloxacin stopped it in its tracks.. a few days later I was walking to the supermarket and my Achillies tendon started to crunch and I was in extreme pain.. Got 100 metres and had to crawl back home on my hands and knees.. I was 34.. I researched it and took magnesium supplements twice a day and the problem resolved near instantly.....

Cipro has its place in acute antimicrobial therapy combined with magnesium supplementation.. but it's easily weaponised.

Achillies tendon rupture.. a debilitating injury is an unacceptably high outcome without magnesium supplementation”

<https://regenerativemedicinela.com/treatments/fluoroquinolone-toxicity-treatment/>

Urgent Request

The amount of Ciprofloxacin in the MPOX jab is said to be a trace amount – Only 0.005 micrograms.

However, due to imminent global rollout, independent quantitative tests on these vaccines are urgently needed to verify ingredient quantities in each dose. During Covid we saw that some ingredients were undisclosed - e.g. SV40, amyloidogenic sequences, plasmids etc. It is not beyond possible that stated concentrations of Ciprofloxacin in the MPOX vials are lower than actual concentrations. Declared amounts should not be taken on trust.

Undoubtedly, children in schools will be targeted for mass vaccination with the MPOX jab. We definitely need to test these jabs ASAP to avoid possible catastrophic injury.

Heart Damage Still a Danger

Note that the MPOX vaccine is a repurposed smallpox vaccine and is associated with increased troponin levels and heart damage. See the Jynneos package insert here– [download \(fda.gov\)](#)

The risk of heart damage has to be weighed against the effect of a very rare and exotic disease, against which your natural immune system offers the best protection.

A school population may experience a high incidence of heart damage caused by the MPOX vaccine. This will adversely affect lives. Such disability would be an intolerable burden on poorer families who rely on their children to help with everyday household and rural tasks.

Gentamicin

This is another ingredient in the MPOX vaccine. It is only present in trace amounts.

Here are the symptoms associated with Gentamicin in the Eudra-vigilance database - [download here](#)

| SYMPTOM | FREQ | TOTAL | % |
|---|------|-------|-------|
| acute kidney injury | 210 | 1685 | 12.46 |
| renal failure | 54 | 1685 | 3.2 |
| anaphylactic reaction | 42 | 1685 | 2.49 |
| rash | 41 | 1685 | 2.43 |
| renal tubular necrosis | 29 | 1685 | 1.72 |
| drug ineffective | 28 | 1685 | 1.66 |
| hypotension | 26 | 1685 | 1.54 |
| pyrexia | 24 | 1685 | 1.42 |
| pruritus | 23 | 1685 | 1.36 |
| renal impairment | 22 | 1685 | 1.31 |
| urticaria | 17 | 1685 | 1.01 |
| erythema | 16 | 1685 | 0.95 |
| rash maculo-papular | 15 | 1685 | 0.89 |
| dizziness | 14 | 1685 | 0.83 |
| nephropathy toxic | 14 | 1685 | 0.83 |
| condition aggravated | 14 | 1685 | 0.83 |
| nausea | 13 | 1685 | 0.77 |
| drug interaction | 13 | 1685 | 0.77 |
| rash erythematous | 13 | 1685 | 0.77 |
| drug reaction with eosinophilia and systemic symptoms | 12 | 1685 | 0.71 |
| drug level increased | 12 | 1685 | 0.71 |
| eye infection intraocular | 12 | 1685 | 0.71 |
| thrombocytopenia | 12 | 1685 | 0.71 |
| neutropenia | 12 | 1685 | 0.71 |

As you can see, the most prominent symptoms are to do with kidney injury.

Help with Legal Cases

If you are engaged in lawsuits against pharma companies for undisclosed adverse effects of any drug, then I am happy to offer a service in support of your cause.

- **SYMPTOM SEARCH** : I can provide an analysis and ranking of all the symptoms for your chosen drug using post-marketing databases such as VAERS and EUDRA. This will show all symptoms for the drug in order of symptom incidence. Such an analysis will identify the most frequent adverse effects, and prioritize them for investigation.
- **LITERATURE SEARCH** : Then I will carry out a literature search to determine the clinical incidence of the symptoms, and provide a final written report.
- **LAW SEARCH** : Finally, I will carry out a search of current lawsuits related to your drug of interest.

My services may give you greater confidence to pursue litigation, and the data provided may increase the probability of a positive verdict.

Please contact Craig Paardekooper at craig_pkooper@yahoo.com, for further information.